메뉴 건너뛰기




Volumn 19, Issue 7, 2013, Pages 1311-1320

Glycine reuptake inhibition as a new therapeutic approach in schizophrenia: Focus on the glycine transporter 1 (GlyT1)

Author keywords

Bitopertin; D cycloserine; Glycine; Glycine receptor; Glycine transporter; GlyT1; Ketamine; Negative symptoms; NMDA receptor; Phencyclidine; Sarcosine; Schizophrenia

Indexed keywords

2 CHLORO N [ALPHA (2 PIPERIDINYL)BENZYL] 3 TRIFLUOROMETHYLBENZAMIDE; BITOPERTIN; CYCLOSERINE; GLYCINE TRANSPORTER 1; GSK 101892; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N [3 (4 FLUOROPHENYL) 3 (4 PHENYLPHENOXY)PROPYL]SARCOSINE; NEUROLEPTIC AGENT; ORG 24461; ORG 25935; RISPERIDONE; SARCOSINE; SSR 103800; UNCLASSIFIED DRUG;

EID: 84876735618     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319070015     Document Type: Article
Times cited : (31)

References (79)
  • 1
    • 39949083194 scopus 로고    scopus 로고
    • Schizophrenia, "Just the Facts": What we know in 2008 part 1: Overview
    • Tandon R, Keshavan MS, Nasrallah HA. Schizophrenia, "Just the Facts": what we know in 2008 part 1: overview. Schizophr Res 2008; 100(1-3): 4-19.
    • (2008) Schizophr Res , vol.100 , Issue.1-3 , pp. 4-19
    • Tandon, R.1    Keshavan, M.S.2    Nasrallah, H.A.3
  • 3
    • 33845797866 scopus 로고    scopus 로고
    • Negative symptoms of schizophrenia: A problem that will not go away
    • Stahl SM, Buckley PF. Negative symptoms of schizophrenia: a problem that will not go away. Acta Psychiatrica Scand 2007; 115: 4-11.
    • (2007) Acta Psychiatrica Scand , vol.115 , pp. 4-11
    • Stahl, S.M.1    Buckley, P.F.2
  • 4
    • 84863866584 scopus 로고    scopus 로고
    • Negative symptoms and psychosocial functioning in schizophrenia: Neglected but important targets for treatment
    • Hunter R, Barry S. Negative symptoms and psychosocial functioning in schizophrenia: Neglected but important targets for treatment. Eur Psychiatry 2012; 27(6): 432-6.
    • (2012) Eur Psychiatry , vol.27 , Issue.6 , pp. 432-436
    • Hunter, R.1    Barry, S.2
  • 5
    • 70449641202 scopus 로고    scopus 로고
    • Second-generation antipsychotics for schizophrenia: Can we resolve the conflict?
    • Leucht S, Kissling W, Davis JM. Second-generation antipsychotics for schizophrenia: can we resolve the conflict? Psychol Med 2009; 39: 1591-602.
    • (2009) Psychol Med , vol.39 , pp. 1591-1602
    • Leucht, S.1    Kissling, W.2    Davis, J.M.3
  • 6
    • 34548548362 scopus 로고    scopus 로고
    • Clinical evaluation of negative symptoms in schizophrenia
    • Moller HJ. Clinical evaluation of negative symptoms in schizophrenia. Eur Psychiatry 2007; 22: 380-6.
    • (2007) Eur Psychiatry , vol.22 , pp. 380-386
    • Moller, H.J.1
  • 7
    • 0017255979 scopus 로고
    • Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs
    • Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976; 192: 481-3.
    • (1976) Science , vol.192 , pp. 481-483
    • Creese, I.1    Burt, D.R.2    Snyder, S.H.3
  • 8
    • 0028850552 scopus 로고
    • Glutamate receptor dysfunction and schizophrenia
    • Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995; 52: 998-1007.
    • (1995) Arch Gen Psychiatry , vol.52 , pp. 998-1007
    • Olney, J.W.1    Farber, N.B.2
  • 9
    • 77149138329 scopus 로고    scopus 로고
    • Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: Too little juice or a miswired brain?
    • Marek GJ, Behl B, Bespalov AY, et al. Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain? Mol Pharmacol 2010; 77: 317-26.
    • (2010) Mol Pharmacol , vol.77 , pp. 317-326
    • Marek, G.J.1    Behl, B.2    Bespalov, A.Y.3
  • 10
    • 77956648156 scopus 로고    scopus 로고
    • N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: The final common pathway on the road to schizophrenia?
    • Kantrowitz JT, Javitt DC. N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia? Brain Res Bull 2010; 83: 108-21.
    • (2010) Brain Res Bull , vol.83 , pp. 108-121
    • Kantrowitz, J.T.1    Javitt, D.C.2
  • 11
    • 78149284957 scopus 로고    scopus 로고
    • Glycine transport inhibitors for the treatment of schizophrenia
    • Hashimoto K. Glycine transport inhibitors for the treatment of schizophrenia. Open Med Chem J 2010; 4: 10-9.
    • (2010) Open Med Chem J , vol.4 , pp. 10-19
    • Hashimoto, K.1
  • 12
    • 0023091647 scopus 로고
    • Glycine potentiates the NMDA response in cultured mouse brain neurons
    • Johnson JW, Ascher P. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature 1987; 325: 529-31.
    • (1987) Nature , vol.325 , pp. 529-531
    • Johnson, J.W.1    Ascher, P.2
  • 13
    • 0032429754 scopus 로고    scopus 로고
    • Glycine and N-methyl-D-aspartate receptors: Physiological significance and possible therapeutic applications
    • Danysz W, Parsons CG. Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications. Pharmacol Rev 1998; 50: 597-664.
    • (1998) Pharmacol Rev , vol.50 , pp. 597-664
    • Danysz, W.1    Parsons, C.G.2
  • 14
    • 0023754192 scopus 로고
    • Requirement for glycine in activation of NMDA-receptors expressed in Xenopus oocytes
    • Kleckner NW, Dingledine R. Requirement for glycine in activation of NMDA-receptors expressed in Xenopus oocytes. Science 1988; 241: 835-7.
    • (1988) Science , vol.241 , pp. 835-837
    • Kleckner, N.W.1    Dingledine, R.2
  • 15
    • 84864634182 scopus 로고    scopus 로고
    • Synaptic and extrasynaptic NMDA receptors are gated by different endogenous coagonists
    • Papouin T, Ladépêche L, Ruel J, et al. Synaptic and extrasynaptic NMDA receptors are gated by different endogenous coagonists. Cell 2012; 150(3): 633-46.
    • (2012) Cell , vol.150 , Issue.3 , pp. 633-646
    • Papouin, T.1    Ladépêche, L.2    Ruel, J.3
  • 16
    • 84863337898 scopus 로고    scopus 로고
    • Opposing roles of synaptic and extrasynaptic NMDA receptor signaling in cocultured striatal and cortical neurons
    • Kaufman AM, Milnerwood AJ, Sepers MD, et al. Opposing roles of synaptic and extrasynaptic NMDA receptor signaling in cocultured striatal and cortical neurons. J Neurosci 2012; 32(12): 3992-4003.
    • (2012) J Neurosci , vol.32 , Issue.12 , pp. 3992-4003
    • Kaufman, A.M.1    Milnerwood, A.J.2    Sepers, M.D.3
  • 17
    • 84863148838 scopus 로고    scopus 로고
    • Functional roles of synaptic and extrasynaptic NMDA receptors in physiological and pathological neuronal activities
    • Li ST, Ju JG. Functional roles of synaptic and extrasynaptic NMDA receptors in physiological and pathological neuronal activities. Curr Drug Targets 2012; 13(2): 207-21.
    • (2012) Curr Drug Targets , vol.13 , Issue.2 , pp. 207-221
    • Li, S.T.1    Ju, J.G.2
  • 18
    • 80053221118 scopus 로고    scopus 로고
    • Translating glutamate: From pathophysiology to treatment
    • Javitt DC, Schoepp D, Kalivas PW, et al. Translating glutamate: from pathophysiology to treatment. Sci Transl Med 2011; 3(102): 102mr2.
    • (2011) Sci Transl Med , vol.3 , Issue.102
    • Javitt, D.C.1    Schoepp, D.2    Kalivas, P.W.3
  • 19
    • 34547634946 scopus 로고    scopus 로고
    • Phencyclidine and genetic animal models of schizophrenia developed in relation to the glutamate hypothesis
    • Enomoto T, Noda Y, Nabeshima T. Phencyclidine and genetic animal models of schizophrenia developed in relation to the glutamate hypothesis. Methods Find Exp Clin Pharmacol 2007; 29(4): 291-301.
    • (2007) Methods Find Exp Clin Pharmacol , vol.29 , Issue.4 , pp. 291-301
    • Enomoto, T.1    Noda, Y.2    Nabeshima, T.3
  • 20
    • 0019293020 scopus 로고
    • Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia
    • Kim JS, Kornhuber HH, Schmid-Burgk W, et al. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett 1980; 20: 379-82.
    • (1980) Neurosci Lett , vol.20 , pp. 379-382
    • Kim, J.S.1    Kornhuber, H.H.2    Schmid-Burgk, W.3
  • 21
    • 12344327212 scopus 로고    scopus 로고
    • Schizophrenia genes, gene expression, and neuropathology: On the matter of their convergence
    • Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 2005; 10: 40-68.
    • (2005) Mol Psychiatry , vol.10 , pp. 40-68
    • Harrison, P.J.1    Weinberger, D.R.2
  • 22
    • 68549099832 scopus 로고    scopus 로고
    • Positive and negative symptoms in schizophrenia: The NMDA receptor hypofunction hypothesis, neuregulin/ErbB4 and synapse regression
    • Bennett M. Positive and negative symptoms in schizophrenia: the NMDA receptor hypofunction hypothesis, neuregulin/ErbB4 and synapse regression. Aust N Z J Psychiatry 2009; 43(8): 711-21.
    • (2009) Aust N Z J Psychiatry , vol.43 , Issue.8 , pp. 711-721
    • Bennett, M.1
  • 23
    • 0025952455 scopus 로고
    • Recent advances in the phencyclidine model of schizophrenia
    • Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991; 148: 1301-8.
    • (1991) Am J Psychiatry , vol.148 , pp. 1301-1308
    • Javitt, D.C.1    Zukin, S.R.2
  • 24
    • 0001979163 scopus 로고
    • Comparison of phencyclidine hydrochloride (Sernyl) with other drugs. Simulation of schizophrenic performance with phencyclidine hydrochloride (Sernyl), lysergic acid diethylamide (LSD-25), and amobarbital (Amytal) sodium; II. Symbolic and sequential thinking
    • Cohen BD, Rosenbaum G, Luby ED, et al. Comparison of phencyclidine hydrochloride (Sernyl) with other drugs. Simulation of schizophrenic performance with phencyclidine hydrochloride (Sernyl), lysergic acid diethylamide (LSD-25), and amobarbital (Amytal) sodium; II. Symbolic and sequential thinking. Arch Gen Psychiatry 1962; 6: 395-401.
    • (1962) Arch Gen Psychiatry , vol.6 , pp. 395-401
    • Cohen, B.D.1    Rosenbaum, G.2    Luby, E.D.3
  • 26
    • 70449270240 scopus 로고
    • Comparison of sernyl with other drugs: Simulation of schizophrenic performance with sernyl, LSD-25, and amobarbital (amytal) sodium; I. Attention, motor function, and proprioception
    • Rosenbaum G, Cohen BD, Luby ED, et al. Comparison of sernyl with other drugs: simulation of schizophrenic performance with sernyl, LSD-25, and amobarbital (amytal) sodium; I. Attention, motor function, and proprioception. AMA Arch Gen Psychiatry 1959; 1: 651-6.
    • (1959) AMA Arch Gen Psychiatry , vol.1 , pp. 651-656
    • Rosenbaum, G.1    Cohen, B.D.2    Luby, E.D.3
  • 28
    • 0029927565 scopus 로고    scopus 로고
    • NMDA receptor function and human cognition: The effects of ketamine in healthy volunteers
    • Malhotra AK, Pinals DA, Weingartner H, et al. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 1996; 14: 301-7.
    • (1996) Neuropsychopharmacology , vol.14 , pp. 301-307
    • Malhotra, A.K.1    Pinals, D.A.2    Weingartner, H.3
  • 29
    • 84858154998 scopus 로고    scopus 로고
    • NMDA antagonists recreate signal-to-noise ratio and timing perturbations present in schizophrenia
    • Saunders JA, Gandal MJ, Siegel SJ. NMDA antagonists recreate signal-to-noise ratio and timing perturbations present in schizophrenia. Neurobiol Dis 2012; 46: 93-100.
    • (2012) Neurobiol Dis , vol.46 , pp. 93-100
    • Saunders, J.A.1    Gandal, M.J.2    Siegel, S.J.3
  • 30
    • 0036501435 scopus 로고    scopus 로고
    • Mismatch negativity predicts psychotic experiences induced by NMDA receptor antagonist in healthy volunteers
    • Umbricht D, Koller R, Vollenweider FX, Schmid L. Mismatch negativity predicts psychotic experiences induced by NMDA receptor antagonist in healthy volunteers. Biol Psychiatry 2002; 51(5): 400-6.
    • (2002) Biol Psychiatry , vol.51 , Issue.5 , pp. 400-406
    • Umbricht, D.1    Koller, R.2    Vollenweider, F.X.3    Schmid, L.4
  • 31
    • 0014201598 scopus 로고
    • Association of glycine with spinal interneurones
    • Davidoff RA, Shank RP, Graham LT, Jr. et al. Association of glycine with spinal interneurones. Nature 1967; 214: 680-1.
    • (1967) Nature , vol.214 , pp. 680-681
    • Davidoff, R.A.1    Shank, R.P.2    Graham Jr., L.T.3
  • 32
    • 84890882915 scopus 로고    scopus 로고
    • Localization of glycine receptors in the human forebrain, brainstem, and cervical spinal cord: An immunohistochemical review
    • Baer K, Waldvogel HJ, Faull RL, et al. Localization of glycine receptors in the human forebrain, brainstem, and cervical spinal cord: an immunohistochemical review. Front Mol Neurosci 2009; 2: 25.
    • (2009) Front Mol Neurosci , vol.2 , pp. 25
    • Baer, K.1    Waldvogel, H.J.2    Faull, R.L.3
  • 33
    • 4644265039 scopus 로고    scopus 로고
    • Molecular structure and function of the glycine receptor chloride channel
    • Lynch JW. Molecular structure and function of the glycine receptor chloride channel. Physiol Rev 2004; 84: 1051-95.
    • (2004) Physiol Rev , vol.84 , pp. 1051-1095
    • Lynch, J.W.1
  • 34
    • 0037074985 scopus 로고    scopus 로고
    • Excitatory glycine receptors containing the NR3 family of NMDA receptor subunits
    • Chatterton JE, Awobuluyi M, Premkumar LS, et al. Excitatory glycine receptors containing the NR3 family of NMDA receptor subunits. Nature 2002; 415(6873): 793-8.
    • (2002) Nature , vol.415 , Issue.6873 , pp. 793-798
    • Chatterton, J.E.1    Awobuluyi, M.2    Premkumar, L.S.3
  • 35
    • 70949105241 scopus 로고    scopus 로고
    • Glycine as a neurotransmitter in the forebrain: A short review
    • Hernandes MS, Troncone LR. Glycine as a neurotransmitter in the forebrain: a short review. J Neural Transm 2009; 116: 1551-60.
    • (2009) J Neural Transm , vol.116 , pp. 1551-1560
    • Hernandes, M.S.1    Troncone, L.R.2
  • 36
    • 0031056559 scopus 로고    scopus 로고
    • Cell-type specific organization of glycine receptor clusters in the mammalian spinal cord
    • Alvarez FJ, Dewey DE, Harrington DA, et al. Cell-type specific organization of glycine receptor clusters in the mammalian spinal cord. J Comp Neurol 1997; 379: 150-70.
    • (1997) J Comp Neurol , vol.379 , pp. 150-170
    • Alvarez, F.J.1    Dewey, D.E.2    Harrington, D.A.3
  • 37
    • 20444391684 scopus 로고    scopus 로고
    • Glycine transporters: Essential regulators of neurotransmission
    • Eulenburg V, Armsen W, Betz H, et al. Glycine transporters: essential regulators of neurotransmission. Trends Biochem Sci 2005; 30: 325-33.
    • (2005) Trends Biochem Sci , vol.30 , pp. 325-333
    • Eulenburg, V.1    Armsen, W.2    Betz, H.3
  • 38
    • 0029014595 scopus 로고
    • Regional distribution and developmental variation of the glycine transporters GLYT1 and GLYT2 in the rat CNS
    • Zafra F, Gomeza J, Olivares L, et al. Regional distribution and developmental variation of the glycine transporters GLYT1 and GLYT2 in the rat CNS. Eur J Neurosci 1995; 7: 1342-52.
    • (1995) Eur J Neurosci , vol.7 , pp. 1342-1352
    • Zafra, F.1    Gomeza, J.2    Olivares, L.3
  • 39
    • 15244347525 scopus 로고    scopus 로고
    • Localization of the GLYT1 glycine transporter at glutamatergic synapses in the rat brain
    • Cubelos B, Gimenez C, Zafra F. Localization of the GLYT1 glycine transporter at glutamatergic synapses in the rat brain. Cereb Cortex 2005; 15: 448-59.
    • (2005) Cereb Cortex , vol.15 , pp. 448-459
    • Cubelos, B.1    Gimenez, C.2    Zafra, F.3
  • 40
    • 0024535309 scopus 로고
    • Characteristics and adaptive regulation of glycine transport in cultured glial cells
    • Zafra F, Gimenez C. Characteristics and adaptive regulation of glycine transport in cultured glial cells. Biochem J 1989; 258: 403-8.
    • (1989) Biochem J , vol.258 , pp. 403-408
    • Zafra, F.1    Gimenez, C.2
  • 41
    • 0028860260 scopus 로고
    • Localization of glycine neurotransmitter transporter (GLYT2) reveals correlation with the distribution of glycine receptor
    • Jursky F, Nelson N. Localization of glycine neurotransmitter transporter (GLYT2) reveals correlation with the distribution of glycine receptor. J Neurochem 1995; 64: 1026-33.
    • (1995) J Neurochem , vol.64 , pp. 1026-1033
    • Jursky, F.1    Nelson, N.2
  • 42
    • 10744221393 scopus 로고    scopus 로고
    • Inactivation of the glycine transporter 1 gene discloses vital role of glial glycine uptake in glycinergic inhibition
    • Gomeza J, Hulsmann S, Ohno K, et al. Inactivation of the glycine transporter 1 gene discloses vital role of glial glycine uptake in glycinergic inhibition. Neuron 2003; 40: 785-96.
    • (2003) Neuron , vol.40 , pp. 785-796
    • Gomeza, J.1    Hulsmann, S.2    Ohno, K.3
  • 43
    • 55749110913 scopus 로고    scopus 로고
    • The glycine transporter GlyT2 controls the dynamics of synaptic vesicle refilling in inhibitory spinal cord neurons
    • Rousseau F, Aubrey KR, Supplisson S. The glycine transporter GlyT2 controls the dynamics of synaptic vesicle refilling in inhibitory spinal cord neurons. J Neurosci 2008; 28: 9755-68.
    • (2008) J Neurosci , vol.28 , pp. 9755-9768
    • Rousseau, F.1    Aubrey, K.R.2    Supplisson, S.3
  • 44
    • 0030919910 scopus 로고    scopus 로고
    • Control of NMDA receptor activation by a glycine transporter co-expressed in Xenopus oocytes
    • Supplisson S, Bergman C. Control of NMDA receptor activation by a glycine transporter co-expressed in Xenopus oocytes. J Neurosci 1997; 17: 4580-90.
    • (1997) J Neurosci , vol.17 , pp. 4580-4590
    • Supplisson, S.1    Bergman, C.2
  • 45
    • 3042542923 scopus 로고    scopus 로고
    • Glycine transporter type 1 blockade changes NMDA receptor-mediated responses and LTP in hippocampal CA1 pyramidal cells by altering extracellular glycine levels
    • Martina M, Gorfinkel Y, Halman S, et al. Glycine transporter type 1 blockade changes NMDA receptor-mediated responses and LTP in hippocampal CA1 pyramidal cells by altering extracellular glycine levels. J Physiol 2004; 557: 489-500.
    • (2004) J Physiol , vol.557 , pp. 489-500
    • Martina, M.1    Gorfinkel, Y.2    Halman, S.3
  • 46
    • 0036455132 scopus 로고    scopus 로고
    • Potentiation of inhibitory glycinergic neurotransmission by Zn2+: A synergistic interplay between presynaptic P2X2 and postsynaptic glycine receptors
    • Laube B. Potentiation of inhibitory glycinergic neurotransmission by Zn2+: a synergistic interplay between presynaptic P2X2 and postsynaptic glycine receptors. Eur J Neurosci 2002; 16: 1025-36.
    • (2002) Eur J Neurosci , vol.16 , pp. 1025-1036
    • Laube, B.1
  • 47
    • 77953289841 scopus 로고    scopus 로고
    • D-Serine and a glycine transporter-1 inhibitor enhance social memory in rats
    • Shimazaki T, Kaku A, Chaki S. D-Serine and a glycine transporter-1 inhibitor enhance social memory in rats. Psychopharmacology (Berl) 2010; 209: 263-70.
    • (2010) Psychopharmacology (Berl) , vol.209 , pp. 263-270
    • Shimazaki, T.1    Kaku, A.2    Chaki, S.3
  • 48
    • 0029658545 scopus 로고    scopus 로고
    • Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia
    • Heresco-Levy U, Javitt DC, Ermilov M, et al. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br J Psychiatry 1996; 169: 610-7.
    • (1996) Br J Psychiatry , vol.169 , pp. 610-617
    • Heresco-Levy, U.1    Javitt, D.C.2    Ermilov, M.3
  • 49
    • 0032925438 scopus 로고    scopus 로고
    • Efficacy of highdose glycine in the treatment of enduring negative symptoms of schizophrenia
    • Heresco-Levy U, Javitt DC, Ermilov M, et al. Efficacy of highdose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry 1999; 56: 29-36.
    • (1999) Arch Gen Psychiatry , vol.56 , pp. 29-36
    • Heresco-Levy, U.1    Javitt, D.C.2    Ermilov, M.3
  • 50
    • 0348047434 scopus 로고    scopus 로고
    • Comparative effects of glycine and Dcycloserine on persistent negative symptoms in schizophrenia: A retrospective analysis
    • Heresco-Levy U, Javitt DC. Comparative effects of glycine and Dcycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis. Schizophr Res 2004; 66: 89-96.
    • (2004) Schizophr Res , vol.66 , pp. 89-96
    • Heresco-Levy, U.1    Javitt, D.C.2
  • 51
    • 51049089047 scopus 로고    scopus 로고
    • Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs. cortical brain areas
    • Perry KW, Falcone JF, Fell MJ, et al. Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs. cortical brain areas. Neuropharmacology 2008 55(5): 743-54.
    • (2008) Neuropharmacology , vol.55 , Issue.5 , pp. 743-754
    • Perry, K.W.1    Falcone, J.F.2    Fell, M.J.3
  • 52
    • 0041920952 scopus 로고    scopus 로고
    • The glycine transporter type 1 inhibitor N-[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl]sarcosine potentiates NMDA receptor-mediated responses in vivo and produces an antipsychotic profile in rodent behavior
    • Kinney GG, Sur C, Burno M, et al. The glycine transporter type 1 inhibitor N-[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl]sarcosine potentiates NMDA receptor-mediated responses in vivo and produces an antipsychotic profile in rodent behavior. J Neurosci 2003; 23: 7586-91.
    • (2003) J Neurosci , vol.23 , pp. 7586-7591
    • Kinney, G.G.1    Sur, C.2    Burno, M.3
  • 53
    • 0842286593 scopus 로고    scopus 로고
    • Reversal of phencyclidineinduced dopaminergic dysregulation by N-methyl-D-aspartate receptor/ glycine-site agonists
    • Javitt DC, Balla A, Burch S, et al. Reversal of phencyclidineinduced dopaminergic dysregulation by N-methyl-D-aspartate receptor/ glycine-site agonists. Neuropsychopharmacology 2004; 29(2): 300-7.
    • (2004) Neuropsychopharmacology , vol.29 , Issue.2 , pp. 300-307
    • Javitt, D.C.1    Balla, A.2    Burch, S.3
  • 54
    • 29744453122 scopus 로고    scopus 로고
    • Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic
    • Depoortere R, Dargazanli G, Estenne-Bouhtou G, et al. Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic. Neuropsychopharmacology 2005; 30: 1963-85.
    • (2005) Neuropsychopharmacology , vol.30 , pp. 1963-1985
    • Depoortere, R.1    Dargazanli, G.2    Estenne-Bouhtou, G.3
  • 55
    • 29744432669 scopus 로고    scopus 로고
    • 2-Chloro-N-[(S)-phenyl [(2S)-piperidin-2-yl] methyl]-3-trifluoromethyl benzamide, mono hydrochloride, an inhibitor of the glycine transporter type 1, increases evoked-dopamine release in the rat nucleus accumbens in vivo via an enhanced glutamatergic neurotransmission
    • Leonetti M, Desvignes C, Bougault I, et al. 2-Chloro-N-[(S)-phenyl [(2S)-piperidin-2-yl] methyl]-3-trifluoromethyl benzamide, mono hydrochloride, an inhibitor of the glycine transporter type 1, increases evoked-dopamine release in the rat nucleus accumbens in vivo via an enhanced glutamatergic neurotransmission. Neuroscience 2006; 137: 555-64.
    • (2006) Neuroscience , vol.137 , pp. 555-564
    • Leonetti, M.1    Desvignes, C.2    Bougault, I.3
  • 56
    • 59449096382 scopus 로고    scopus 로고
    • The glycine transporter 1 inhibitor SSR504734 enhances working memory performance in a continuous delayed alternation task in C57BL/6 mice
    • Singer P, Yee BK, Feldon J, et al. The glycine transporter 1 inhibitor SSR504734 enhances working memory performance in a continuous delayed alternation task in C57BL/6 mice. Psychopharmacology (Berl) 2009; 202: 371-84.
    • (2009) Psychopharmacology (Berl) , vol.202 , pp. 371-384
    • Singer, P.1    Yee, B.K.2    Feldon, J.3
  • 57
    • 59449086656 scopus 로고    scopus 로고
    • Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: Latent inhibition studies in the rat
    • Black MD, Varty GB, Arad M, et al. Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: latent inhibition studies in the rat. Psychopharmacology (Berl) 2009; 202: 385-96.
    • (2009) Psychopharmacology (Berl) , vol.202 , pp. 385-396
    • Black, M.D.1    Varty, G.B.2    Arad, M.3
  • 58
    • 72449178338 scopus 로고    scopus 로고
    • The glycine transporter-1 inhibitor SSR103800 displays a selective and specific antipsychotic-like profile in normal and transgenic mice
    • Boulay D, Bergis O, Avenet P, et al. The glycine transporter-1 inhibitor SSR103800 displays a selective and specific antipsychotic-like profile in normal and transgenic mice. Neuropsychopharmacology 2010; 35: 416-27.
    • (2010) Neuropsychopharmacology , vol.35 , pp. 416-427
    • Boulay, D.1    Bergis, O.2    Avenet, P.3
  • 59
    • 3042691500 scopus 로고    scopus 로고
    • The synthesis and SAR of 2-arylsulfanyl-phenyl piperazinyl acetic acids as glyT-1 inhibitors
    • Smith G, Ruhland T, Mikkelsen G, et al. The synthesis and SAR of 2-arylsulfanyl-phenyl piperazinyl acetic acids as glyT-1 inhibitors. Bioorg Med Chem Lett 2004; 14: 4027-30.
    • (2004) Bioorg Med Chem Lett , vol.14 , pp. 4027-4030
    • Smith, G.1    Ruhland, T.2    Mikkelsen, G.3
  • 60
    • 0037343294 scopus 로고    scopus 로고
    • The glycine transporter-1 inhibitors NFPS and Org 24461: A pharmacological study
    • Harsing LG, Jr., Gacsalyi I, Szabo G, et al. The glycine transporter-1 inhibitors NFPS and Org 24461: a pharmacological study. Pharmacol Biochem Behav 2003; 74: 811-25.
    • (2003) Pharmacol Biochem Behav , vol.74 , pp. 811-825
    • Harsing Jr., L.G.1    Gacsalyi, I.2    Szabo, G.3
  • 61
    • 78651340371 scopus 로고    scopus 로고
    • Alterations in brain extracellular dopamine and glycine levels following combined administration of the glycine transporter type-1 inhibitor Org-24461 and risperidone
    • Nagy K, Marko B, Zsilla G, et al. Alterations in brain extracellular dopamine and glycine levels following combined administration of the glycine transporter type-1 inhibitor Org-24461 and risperidone. Neurochem Res 2010; 35: 2096-106.
    • (2010) Neurochem Res , vol.35 , pp. 2096-2106
    • Nagy, K.1    Marko, B.2    Zsilla, G.3
  • 62
    • 84876741336 scopus 로고    scopus 로고
    • Pre-clinical characterization of [(11)C]R05013853 as a novel radiotracer for imaging of the glycine transporter type 1 by positron emission tomography
    • Dec 10
    • Borroni E, Zhou Y, Ostrowitzki S, et al. Pre-clinical characterization of [(11)C]R05013853 as a novel radiotracer for imaging of the glycine transporter type 1 by positron emission tomography. Neuroimage 2011 Dec 10.
    • (2011) Neuroimage
    • Borroni, E.1    Zhou, Y.2    Ostrowitzki, S.3
  • 63
    • 84855979108 scopus 로고    scopus 로고
    • Glycine reuptake inhibitor RG1678: A pharmacologic characterization of an investigational agent for the treatment of schizophrenia
    • Alberati D, Moreau JL, Lengyel J, et al. Glycine reuptake inhibitor RG1678: a pharmacologic characterization of an investigational agent for the treatment of schizophrenia. Neuropharmacology 2012; 62: 1152-61.
    • (2012) Neuropharmacology , vol.62 , pp. 1152-1161
    • Alberati, D.1    Moreau, J.L.2    Lengyel, J.3
  • 64
    • 0033923220 scopus 로고    scopus 로고
    • Animal models for the negative symptoms of schizophrenia
    • Ellenbroek BA, Cools AR. Animal models for the negative symptoms of schizophrenia. Behav Pharmacol 2000; 11: 223-33.
    • (2000) Behav Pharmacol , vol.11 , pp. 223-233
    • Ellenbroek, B.A.1    Cools, A.R.2
  • 65
    • 78049250838 scopus 로고    scopus 로고
    • Animal models of cognitive dysfunction and negative symptoms of schizophrenia: Focus on NMDA receptor antagonism
    • Neill JC, Barnes S, Cook S, et al. Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism. Pharmacol Ther 2010; 128: 419-32.
    • (2010) Pharmacol Ther , vol.128 , pp. 419-432
    • Neill, J.C.1    Barnes, S.2    Cook, S.3
  • 66
    • 79957791056 scopus 로고    scopus 로고
    • Blockade of glycine transporter 1 by SSR-504734 promotes cognitive flexibility in glycine/NMDA receptor-dependent manner
    • Nikiforuk A, Kos T, Rafa D, et al. Blockade of glycine transporter 1 by SSR-504734 promotes cognitive flexibility in glycine/NMDA receptor-dependent manner. Neuropharmacology 2011; 61(1-2): 262-7.
    • (2011) Neuropharmacology , vol.61 , Issue.1-2 , pp. 262-267
    • Nikiforuk, A.1    Kos, T.2    Rafa, D.3
  • 67
    • 57349094379 scopus 로고    scopus 로고
    • Design of potent GlyT1 inhibitors: In vitro and in vivo profiles
    • Bridges TM, Williams R, Lindsley CW. Design of potent GlyT1 inhibitors: in vitro and in vivo profiles. Curr Opin Mol Ther 2008; 10(6): 591-601.
    • (2008) Curr Opin Mol Ther , vol.10 , Issue.6 , pp. 591-601
    • Bridges, T.M.1    Williams, R.2    Lindsley, C.W.3
  • 68
    • 77953545879 scopus 로고    scopus 로고
    • A randomized, double-blind, placebo-controlled comparison study of sarcosine (Nmethylglycine) and D-serine add-on treatment for schizophrenia
    • Lane HY, Lin CH, Huang YJ, et al. A randomized, double-blind, placebo-controlled comparison study of sarcosine (Nmethylglycine) and D-serine add-on treatment for schizophrenia. Int J Neuropsychopharmacol 2010; 13: 451-60.
    • (2010) Int J Neuropsychopharmacol , vol.13 , pp. 451-460
    • Lane, H.Y.1    Lin, C.H.2    Huang, Y.J.3
  • 69
    • 1542617755 scopus 로고    scopus 로고
    • Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia
    • Tsai G, Lane HY, Yang P, Chong MY, Lange N. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 2004; 55: 452-6.
    • (2004) Biol Psychiatry , vol.55 , pp. 452-456
    • Tsai, G.1    Lane, H.Y.2    Yang, P.3    Chong, M.Y.4    Lange, N.5
  • 70
    • 33748751382 scopus 로고    scopus 로고
    • Glycine transporter 1 inhibitor, Nmethylglycine (sarcosine), added to clozapine for the treatment of schizophrenia
    • Lane HY, Huang CL, Wu PL, et al. Glycine transporter 1 inhibitor, Nmethylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. Biol Psychiatry 2006; 60: 645-9.
    • (2006) Biol Psychiatry , vol.60 , pp. 645-649
    • Lane, H.Y.1    Huang, C.L.2    Wu, P.L.3
  • 71
    • 36849071470 scopus 로고    scopus 로고
    • Sarcosine (N-methylglycine) treatment for acute schizophrenia: A randomized, double-blind study
    • Lane HY, Liu YC, Huang CL, et al. Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study. Biol Psychiatry 2008; 63: 9-12.
    • (2008) Biol Psychiatry , vol.63 , pp. 9-12
    • Lane, H.Y.1    Liu, Y.C.2    Huang, C.L.3
  • 72
    • 80052965562 scopus 로고    scopus 로고
    • First-time-in-human study with GSK1018921, a selective GlyT1 inhibitor: Relationship between exposure and dizziness
    • Ouellet D, Sutherland S, Wang T, et al. First-time-in-human study with GSK1018921, a selective GlyT1 inhibitor: relationship between exposure and dizziness. Clin Pharmacol Ther 2011; 90: 597-604.
    • (2011) Clin Pharmacol Ther , vol.90 , pp. 597-604
    • Ouellet, D.1    Sutherland, S.2    Wang, T.3
  • 73
    • 84857039780 scopus 로고    scopus 로고
    • Glycine transporter inhibitor attenuates the psychotomimetic effects of ketamine in healthy males: Preliminary evidence
    • D'Souza DC, Singh N, Elander J, et al. Glycine transporter inhibitor attenuates the psychotomimetic effects of ketamine in healthy males: preliminary evidence. Neuropsychopharmacology 2012; 37: 1036-46.
    • (2012) Neuropsychopharmacology , vol.37 , pp. 1036-1046
    • D'Souza, D.C.1    Singh, N.2    Elander, J.3
  • 74
    • 35748969317 scopus 로고    scopus 로고
    • The cognitive and negative symptoms in schizophrenia trial (CONSIST): The efficacy of glutamatergic agents for negative symptoms and cognitive impairments
    • Buchanan RW, Javitt DC, Marder SR, et al. The cognitive and negative symptoms in schizophrenia trial (CONSIST): The efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry 2007; 164: 1593-602.
    • (2007) Am J Psychiatry , vol.164 , pp. 1593-1602
    • Buchanan, R.W.1    Javitt, D.C.2    Marder, S.R.3
  • 75
    • 80053229847 scopus 로고    scopus 로고
    • Glycine transporter type 1 (GLYT1) inhibition RG1678: Results of the proof-ofconcept study for the treatment of negative symptoms in schizophrenia
    • Umbricht D, Martin-Facklam M, Pizzagalli E, et al. Glycine transporter type 1 (GLYT1) inhibition RG1678: Results of the proof-ofconcept study for the treatment of negative symptoms in schizophrenia. Schiz Bull 2011; 37(1): 324.
    • (2011) Schiz Bull , vol.37 , Issue.1 , pp. 324
    • Umbricht, D.1    Martin-Facklam, M.2    Pizzagalli, E.3
  • 76
    • 67649989298 scopus 로고    scopus 로고
    • Glycine transport inhibitors for the treatment of schizophrenia: Symptom and disease modification
    • Javitt DC. Glycine transport inhibitors for the treatment of schizophrenia: symptom and disease modification. Curr Opin Drug Discov Devel 2009; 12(4): 468-78.
    • (2009) Curr Opin Drug Discov Devel , vol.12 , Issue.4 , pp. 468-478
    • Javitt, D.C.1
  • 77
    • 77949372130 scopus 로고    scopus 로고
    • Recent progress in the discovery of nonsarcosine based GlyT1 inhibitors
    • Wolkenberg SE, Sur C. Recent progress in the discovery of nonsarcosine based GlyT1 inhibitors. Curr Top Med Chem 2010; 10(2): 170-86.
    • (2010) Curr Top Med Chem , vol.10 , Issue.2 , pp. 170-186
    • Wolkenberg, S.E.1    Sur, C.2
  • 78
    • 34547666657 scopus 로고    scopus 로고
    • Persistent negative symptoms in schizophrenia: An overview
    • Buchanan RW. Persistent negative symptoms in schizophrenia: an overview. Schizophr Bull 2007 33(4): 1013-22.
    • (2007) Schizophr Bull , vol.33 , Issue.4 , pp. 1013-1022
    • Buchanan, R.W.1
  • 79
    • 84861339892 scopus 로고    scopus 로고
    • A novel glycine transporter-1 (GlyT1) inhibitor, ASP2535 (4-[3-isopropyl-5-(6-phenyl-3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole), improves cognition in animal models of cognitive impairment in schizophrenia and Alzheimer's disease
    • Harada K, Nakato K, Yarimizu J, et al. A novel glycine transporter-1 (GlyT1) inhibitor, ASP2535 (4-[3-isopropyl-5-(6-phenyl-3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole), improves cognition in animal models of cognitive impairment in schizophrenia and Alzheimer's disease. Eur J Pharmacol 2012; 685(1-3): 59-69.
    • (2012) Eur J Pharmacol , vol.685 , Issue.1-3 , pp. 59-69
    • Harada, K.1    Nakato, K.2    Yarimizu, J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.